What did @jessiwiththejuice actually say?
The transcript here is heavily garbled, likely a speech-to-text failure on a video with background noise. What comes through clearly enough to evaluate is an injection demonstration. She references drawing air out of a vial, flipping it over, drawing medication to a line, wiping the injection site, going in "straight" or at an angle, holding the injection for a moment, and waiting for the medication to fully dispense. She also mentions moving to a new dose of 30 units and being five weeks into her tirzepatide journey. The nursing credential she references matters here because it sets viewer expectations that this is clinical-grade guidance.
Given the hashtags and caption context, this appears to be a home subcutaneous injection tutorial for a compounded or pen-form GLP-1 medication, almost certainly tirzepatide based on the hashtags.
Does the science back this up?
Most of what she demonstrates aligns with established subcutaneous injection technique, though the garbled transcript makes precise evaluation difficult. The core steps she describes, expelling air from the vial, drawing to a marked line, wiping the site, and holding after injection, are consistent with FDA-cleared subcutaneous injection guidance and standard nursing protocol.
The comment about subcutaneous fat, "it's not even muscle, so cute means it's not a little skin," appears to be her explaining why angle matters less in a fatty area. That is actually correct. Research on subcutaneous injection technique (Hirsch et al., 2014, Journal of Diabetes Science and Technology) confirms that in areas with adequate subcutaneous tissue, a 90-degree angle is appropriate and reduces the risk of intramuscular injection, which can alter absorption and increase bruising.
Holding the injection site briefly after administration is also supported. For viscous medications delivered via syringe rather than auto-injector pen, brief pressure reduces leakage and improves local absorption. This is not controversial in nursing literature.
What did they get wrong (or right)?
Credit where it is due: the technique fragments that survive the transcript are largely sound. Flipping the vial, drawing to a line, wiping the site, going straight in at a fatty area, holding briefly, these are textbook subcutaneous injection steps. A nurse demonstrating this is more credible than a random wellness influencer guessing.
What is missing is more important than what is present. There is no mention of needle gauge selection, which matters for comfort and absorption. There is no discussion of site rotation, which is clinically important for people injecting weekly. Lipohypertrophy, the lumpy scar tissue that forms from repeated injections in the same spot, reduces drug absorption significantly. A 2022 study (Gradel et al., Diabetes Care) found that injecting into lipohypertrophic tissue reduced insulin bioavailability by up to 25 percent. The same principle applies to GLP-1 peptides.
The dose reference, "30 units," is not contextualized. Tirzepatide is typically dosed in milligrams, not units. If this is compounded tirzepatide drawn from a vial, "units" on an insulin syringe does not directly translate to milligrams without knowing the concentration of the reconstituted solution. This is a real patient safety gap in the video.
What should you actually know?
If you are self-injecting a compounded GLP-1 medication at home, several things matter that this video either skips or cannot convey through a garbled transcript. First, concentration verification is not optional. Compounded tirzepatide vials vary in concentration depending on the pharmacy. "30 units" on a syringe means nothing medically without knowing how many milligrams per milliliter are in your specific vial. Dosing errors with concentrated solutions can result in significant overdose.
Second, site rotation is not a suggestion. Rotating among the abdomen, outer thigh, and back of the upper arm reduces lipohypertrophy risk and keeps absorption consistent. Third, while subcutaneous injection technique is learnable, a first injection should ideally be supervised by a licensed provider, not a TikTok tutorial, regardless of how qualified the creator is.
Finally, compounded tirzepatide is not the same as Zepbound or Mounjaro. The FDA has explicitly stated that compounded versions are not FDA-approved and may differ in purity, potency, and sterility. FormBlends works only with licensed, regulated providers. Any dosing decisions should happen through your prescriber, not a comment section.